Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun – 15 March 2018 – According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate‐ to advanced‐stage (BCLC stage B/C) HCC to determine the current evidence.

Narjeet S. Khurmi, Yu‐Hui Chang, D. Eric Steidley, Andrew L. Singer, Winston R. Hewitt, Kunam S. Reddy, Adyr A. Moss, Amit K. Mathur – 15 March 2018 – Cardiovascular disease (CVD) is a leading cause of post–liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals.

Chen Qu, Dandan Zheng, Sai Li, Yingjun Liu, Anna Lidofsky, Jacinta A. Holmes, Jianning Chen, Lu He, Lan Wei, Yadi Liao, Hui Yuan, Qimeng Jin, Zelong Lin, Qiaoting Hu, Yuchuan Jiang, Mengxian Tu, Xijun Chen, Weiming Li, Wenyu Lin, Bryan C. Fuchs, Raymond T. Chung, Jian Hong – 14 March 2018 – Spleen tyrosine kinase (SYK) plays a critical role in immune cell signaling pathways and has been reported as a biomarker for human hepatocellular carcinoma (HCC). We sought to investigate the mechanism by which SYK promotes liver fibrosis and to evaluate SYK as a therapeutic target for liver fibrosis.

Tiong Y. Lim, Enoka Gonsalkorala, Mary D. Cannon, Stella Gabeta, Leonie Penna, Nigel D. Heaton, Michael A. Heneghan – 14 March 2018 – Liver transplantation (LT) is a successful treatment for both acute liver failure and end‐stage liver disease. The number of women of reproductive age undergoing LT is increasing. Pregnancy outcomes are favorable, but there is still a lack of prognostic markers. We aimed to identify factors predictive of adverse pregnancy outcomes in LT recipients.

Lisa B. VanWagner, Fasiha Kanwal – 14 March 2018 – With the passage of the Affordable Care Act followed by the physician payment reform, there is an urgent need to better understand the complex relationships between structure (including incentives), processes, and outcomes of health care and, based on this understanding, identify interventions that can ensure delivery of high‐value care to patients with liver disease. As hepatologists, how do we systematically address these issues and ensure that we provide high‐value care to our patients?

Nao Nishida, Masaya Sugiyama, Hiromi Sawai, Sohji Nishina, Aiko Sakai, Jun Ohashi, Seik‐Soon Khor, Keisuke Kakisaka, Takayo Tsuchiura, Keisuke Hino, Ryo Sumazaki, Yasuhiro Takikawa, Kazumoto Murata, Tatsuo Kanda, Osamu Yokosuka, Katsushi Tokunaga, Masashi Mizokami – 13 March 2018 – Approximately 5‐10% of individuals who are vaccinated with a hepatitis B (HB) vaccine designed based on the hepatitis B virus (HBV) genotype C fail to acquire protective levels of antibodies.

James Fung, Ka‐Shing Cheung, Danny Ka‐Ho Wong, Lung‐Yi Mak, Wai‐Pan To, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen – 13 March 2018 – The significance of hepatitis B e‐antigen (HBeAg) seroclearance (ESC) in the long term is not well defined. The current study aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients undergoing ESC. Patients with documented ESC were followed up 3‐ to 6‐monthly.

Deqiang Zhang, Xin Tong, Bradley B. Nelson, Ethan Jin, Julian Sit, Nicholas Charney, Meichan Yang, M. Bishr Omary, Lei Yin – 13 March 2018 – Alcohol liver disease (ALD) is one of the major chronic liver diseases worldwide, ranging from fatty liver, alcoholic hepatitis, cirrhosis, and potentially, hepatocellular carcinoma. Epidemiological studies suggest a potential link between ALD and impaired circadian rhythms, but the role of hepatic circadian proteins in the pathogenesis of ALD remains unknown.

Narayan Ramamurthy, Emanuele Marchi, M. Azim Ansari, Vincent Pedergnana, Angela Mclean, Emma Hudson, STOP HCV consortium, Rory Bowden, Chris C.A. Spencer, Eleanor Barnes, Paul Klenerman – 13 March 2018 – New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat, including those with cirrhosis or infected with HCV genotype 3.

Cynthia A. Moylan, Manal F. Abdelmalek – 13 March 2018